title: Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.
abstract: Early triptan use after headache onset may help improve the efficacy of acute migraine treatment. This may be particularly the case when triptan therapy is combined with a nonsteroidal anti-inflammatory drug (NSAID). The objective of this is to assess whether the combination of frovatriptan 2.5 mg + dexketoprofen 25 or 37.5 mg (FroDex25 and FroDex37.5) is superior to frovatriptan 2.5 mg alone (Frova) in the acute treatment of migraine attacks in patients who took the drug within 30 min from the onset of pain (early use) or after (late use). A total of 314 subjects with a history of migraine with or without aura were randomized into a double-blind, multicenter, parallel group, pilot study to Frova, FroDex25 or FroDex37.5 and were required to treat at least one migraine attack. In the present post hoc analysis, traditional migraine endpoints were compared across study drugs for subgroups of the 279 patients of the full analysis set according to early (n = 172) or late (n = 107) drug use. The proportion of patients pain free at 2 h in the early drug use subgroup was 33 % with Frova, 50 % with FroDex25 and 51 % with FroDex37.5 mg (p = NS combinations vs. monotherapy), while in the late drug use subgroup was 22, 51 and 50 % (p < 0.05 FroDex25 and FroDex37.5 vs. Frova), respectively. Pain-free episodes at 4 h were 54 % for early and 34 % for late use of Frova, 71 and 57 % with FroDex25 and 74 and 68 % with FroDex37.5 (p < 0.05 for early and p < 0.01 for late use vs. Frova). The proportion of sustained pain free at 24 h was 26 % under Frova, 43 % under FroDex25 mg and 40 % under FroDex37.5 mg (p = NS FroDex25 or 37.5 vs. Frova) in the early drug intake subgroup, while it was 19 % under Frova, 43 % under FroDex25 mg and 45 % under FroDex37.5 mg (p < 0.05 FroDex25 and FroDex37.5 vs. Frova) in the late drug intake subgroup. Risk of relapse at 48 h was similar (p = NS) among study drug groups (Frova: 25 %, FroDex25: 21 %, and FroDex37.5: 37 %) for the early as well as for the late drug use subgroup (14, 42 and 32 %). FroDex was found to be more effective than Frova taken either early or late. The intrinsic pharmacokinetic properties of the two single drug components made FroDex combination particularly effective within the 2-48-h window from the onset of the acute migraine attack. The efficacy does not seem to be influenced by the time of drug use relative to the onset of headache.
authors.affiliation: Women's Headache Center, Department of Surgical Sciences, University of Turin, Via Ventimiglia 3, 10126, Turin, Italy, gb.allais@tiscali.it.
authors.forename: Gianni
authors.initials: G
authors.lastname: Allais
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Tullo
authors.forename: Pietro
authors.initials: P
authors.lastname: Cortelli
authors.forename: Piero
authors.initials: P
authors.lastname: Barbanti
authors.forename: Fabio
authors.initials: F
authors.lastname: Valguarnera
authors.forename: Giuliano
authors.initials: G
authors.lastname: Sette
authors.forename: Florindo
authors.initials: F
authors.lastname: D'Onofrio
authors.forename: Marcella
authors.initials: M
authors.lastname: Curone
authors.forename: Dario
authors.initials: D
authors.lastname: Zava
authors.forename: Deborha
authors.initials: D
authors.lastname: Pezzola
authors.forename: Giorgio
authors.initials: G
authors.lastname: Reggiardo
authors.forename: Stefano
authors.initials: S
authors.lastname: Omboni
authors.forename: Fabio
authors.initials: F
authors.lastname: Frediani
authors.forename: Gennaro
authors.initials: G
authors.lastname: Bussone
authors.forename: Chiara
authors.initials: C
authors.lastname: Benedetto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020325:Migraine with Aura / Q000188:drug therapy*; D020326:Migraine without Aura / Q000188:drug therapy*; D059408:Pain Management / Q000379:methods; D010865:Pilot Projects; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014325:Tromethamine / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014325:Tromethamine; D007660:Ketoprofen; C108128:frovatriptan; C118296:dexketoprofen trometamol